<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40884787</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2380-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>JAMA cardiology</Title><ISOAbbreviation>JAMA Cardiol</ISOAbbreviation></Journal><ArticleTitle>Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk: An Individual Participant Data Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e253403</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamacardio.2025.3403</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Mounting evidence suggests transcatheter aortic valve implantation (TAVI) as preferred treatment for patients at low to intermediate surgical risk. However, limitations in study design and statistical power raise concerns about the generalizability of individual randomized clinical trials (RCTs) comparing TAVI and surgical aortic valve replacement (SAVR) to routine clinical practice.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To compare 1-year outcomes of TAVI vs SAVR in patients with severe symptomatic aortic stenosis at low to intermediate surgical risk applying a 2-stage individual participant data (IPD) and aggregate meta-analyses.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="UNASSIGNED">MEDLINE databases were searched for RCTs comparing TAVI and SAVR in patients with aortic stenosis until June 15, 2025.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="UNASSIGNED">RCTs were selected comparing TAVI vs SAVR in patients with severe symptomatic aortic stenosis at low or intermediate surgical risk with 1-year follow-up.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS" NlmCategory="UNASSIGNED">IPD were obtained from all investigator-initiated RCTs (DEDICATE, NOTION, NOTION-2, and UK TAVI) and analyzed in 1- and 2-stage IPD meta-analyses. An overall meta-analysis was performed by adding aggregate data from industry-sponsored RCTs.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary end point was all-cause death or any stroke 1 year after randomization. Secondary end points included all-cause death, any stroke, disabling stroke, cardiovascular death, rehospitalization for cardiovascular cause, myocardial infarction, new-onset atrial fibrillation, new permanent pacemaker implantation, and aortic valve reintervention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The IPD meta-analysis included 4 RCTs comprising 2873 patients (mean [SD] age, 76.7 [5.5] years; 805 [56.1%] male) at low to intermediate surgical risk randomly assigned to TAVI (n&#x2009;=&#x2009;1439) or SAVR (n&#x2009;=&#x2009;1434). At 1 year, the hazard ratio (HR) for the primary end point for TAVI compared to SAVR was 0.73 (95% CI, 0.56-0.95) in the 1-stage and 0.79 (95% CI, 0.49-1.27) in the 2-stage IPD meta-analysis. In the 2-stage overall meta-analysis the HR for the primary end point was 0.76 (95% CI, 0.60-0.97).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">In this IPD meta-analysis of 4 RCTs, and an overall meta-analysis of 8 RCTs of patients with severe symptomatic AS at low to intermediate risk, TAVI was associated with a reduction in the 1-year incidence of all-cause death or any stroke. These findings emphasize TAVI as alternative option in patients at low to intermediate risk. Long-term follow-up is warranted to evaluate sustainability of these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ludwig</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Population Health Innovation, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research Partner Site North, Hamburg/Kiel/L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Foundation, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimek</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardio-CARE, Medizincampus Davos, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bay</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Population Health Innovation, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research Partner Site North, Hamburg/Kiel/L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blankenberg</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Population Health Innovation, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research Partner Site North, Hamburg/Kiel/L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardio-CARE, Medizincampus Davos, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granada</LastName><ForeName>Juan F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Foundation, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildick-Smith</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sussex Cardiac Centre, Brighton and Sussex University Hospitals National Health Service Trust, Brighton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>Jemma</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Aberdeen Centre for Evaluation, University of Aberdeen, Aberdeen, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf8;rgensen</LastName><ForeName>Troels H&#xf8;jsgaard</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leon</LastName><ForeName>Martin B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Foundation, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnussen</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Population Health Innovation, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research Partner Site North, Hamburg/Kiel/L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiele</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research Partner Site North, Hamburg/Kiel/L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Heart Center Leipzig at Leipzig University and Leipzig Heart Science, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf8;rsted Thyregod</LastName><ForeName>Hans Gustav</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendler</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Cleveland Clinic, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Backer</LastName><ForeName>Ole</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toff</LastName><ForeName>William D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziegler</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Population Health Innovation, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardio-CARE, Medizincampus Davos, Davos, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Pietermaritzburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seiffert</LastName><ForeName>Moritz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research Partner Site North, Hamburg/Kiel/L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology and Angiology, BG University Hospital Bergmannsheil, Ruhr-University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Cardiol</MedlineTA><NlmUniqueID>101676033</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement><b>Conflict of Interest Disclosures: </b>Dr Ludwig reported grants from 4C Medical and German Heart Foundation, personal fees from Abbott and Bayer, travel support from Edwards Lifesciences and Shockwave Medical outside the submitted work. Dr Klimek reported working as a biostatistician at Cardio-CARE, which is a 100% nonprofit stock company and a 100% daughter of the K&#xfc;hne Foundation and Cardio-CARE is shareholder of ART-EMIS Hamburg, outside the submitted work. Dr Bay reported grants from Gertraud und Heinz Rose-Stiftung and from the German Heart Foundation outside the submitted work. Dr Granada reported CRO Services for Edwards Lifesciences, Medtronic, and Abbott during the conduct of the study. Dr Hudson reported grants from National Institute for Health Research Health Technology Assessment Programme. Additional support was provided by the National Institute for Health Research Clinical Research Network NIHR HTA and National Institute for Health Research Clinical Research Network funded this research during the conduct of the study. Dr Leon reported grants from Abbott, Boston Scientific, Edwards, and Medtronic and equity in Medinol, Concept, Xenter, and Ancora outside the submitted work. Dr Magnussen reported personal fees from Edwards, AstraZeneca, Novartis, Boehringer Ingelheim/Lilly, Bayer, and Novo Nordisk and grants from German Center for Cardiovascular Research, German Foundation for cardiovascular research, NDD, and Schwiete Foundation outside the submitted work. Dr De Backer reported personal fees from Abbott, Boston Scientific, and Medtronic during the conduct of the study. Dr Toff reported The University of Leicester received grant funding from the National Institute for Health Research for the conduct of the UK TAVI trial. Dr Ziegler reported serving as scientific director and CEO at Cardio-CARE, which is shareholder of ART-EMIS Hamburg, outside the submitted work. Dr Seiffert reported grants from German Center for Cardiovascular Research and German Heart Foundation during the conduct of the study and lecture fees from Abbott Vascular, Amgen, AstraZeneca, Bayer, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Inari Medical, Medtronic, Pfizer, Shockwave Medical, and Siemens Healthineers outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>30</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40884787</ArticleId><ArticleId IdType="pmc">PMC12398772</ArticleId><ArticleId IdType="doi">10.1001/jamacardio.2025.3403</ArticleId><ArticleId IdType="pii">2838480</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e35-e71. doi: 10.1161/CIR.0000000000000932</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000932</ArticleId><ArticleId IdType="pubmed">33332149</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A, Beyersdorf F, Praz F, et al. ; ESC/EACTS Scientific Document Group . 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. doi: 10.1093/eurheartj/ehab395</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab395</ArticleId><ArticleId IdType="pubmed">34453165</ArticleId></ArticleIdList></Reference><Reference><Citation>Blankenberg S, Seiffert M, Vonthein R, et al. ; DEDICATE-DZHK6 Trial Investigators . Transcatheter or surgical treatment of aortic-valve stenosis. N Engl J Med. 2024;390(17):1572-1583. doi: 10.1056/NEJMoa2400685</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2400685</ArticleId><ArticleId IdType="pubmed">38588025</ArticleId></ArticleIdList></Reference><Reference><Citation>Toff WD, Hildick-Smith D, Kovac J, et al. ; UK TAVI Trial Investigators . Effect of transcatheter aortic valve implantation vs surgical aortic valve replacement on all-cause mortality in patients with aortic stenosis: a randomized clinical trial. JAMA. 2022;327(19):1875-1887. doi: 10.1001/jama.2022.5776</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.5776</ArticleId><ArticleId IdType="pmc">PMC9115619</ArticleId><ArticleId IdType="pubmed">35579641</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf8;rgensen TH, Thyregod HGH, Savontaus M, et al. ; NOTION-2 investigators . Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial. Eur Heart J. 2024;45(37):3804-3814. doi: 10.1093/eurheartj/ehae331</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae331</ArticleId><ArticleId IdType="pubmed">38747246</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon MB, Smith CR, Mack MJ, et al. ; PARTNER 2 Investigators . Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609-1620. doi: 10.1056/NEJMoa1514616</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1514616</ArticleId><ArticleId IdType="pubmed">27040324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack MJ, Leon MB, Thourani VH, et al. ; PARTNER 3 Investigators . Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705. doi: 10.1056/NEJMoa1814052</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1814052</ArticleId><ArticleId IdType="pubmed">30883058</ArticleId></ArticleIdList></Reference><Reference><Citation>Popma JJ, Deeb GM, Yakubov SJ, et al. ; Evolut Low Risk Trial Investigators . Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706-1715. doi: 10.1056/NEJMoa1816885</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1816885</ArticleId><ArticleId IdType="pubmed">30883053</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon MJ, Van Mieghem NM, Popma JJ, et al. ; SURTAVI Investigators . Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376(14):1321-1331. doi: 10.1056/NEJMoa1700456</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1700456</ArticleId><ArticleId IdType="pubmed">28304219</ArticleId></ArticleIdList></Reference><Reference><Citation>Thyregod HG, Steinbr&#xfc;chel DA, Ihlemann N, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65(20):2184-2194. doi: 10.1016/j.jacc.2015.03.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.03.014</ArticleId><ArticleId IdType="pubmed">25787196</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi: 10.1186/1471-2288-12-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-12-9</ArticleId><ArticleId IdType="pmc">PMC3313891</ArticleId><ArticleId IdType="pubmed">22297116</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med. 2017;36(5):855-875. doi: 10.1002/sim.7141</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.7141</ArticleId><ArticleId IdType="pmc">PMC5297998</ArticleId><ArticleId IdType="pubmed">27747915</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsahian S, Resche-Rigon M, Chevret S, Porcher R. Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution. Stat Med. 2006;25(24):4267-4278. doi: 10.1002/sim.2684</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2684</ArticleId><ArticleId IdType="pubmed">16960919</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueten-Budde AJ, Putter H, Fiocco M. Investigating hospital heterogeneity with a competing risks frailty model. Stat Med. 2019;38(2):269-288. doi: 10.1002/sim.8002</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8002</ArticleId><ArticleId IdType="pmc">PMC6587741</ArticleId><ArticleId IdType="pubmed">30338563</ArticleId></ArticleIdList></Reference><Reference><Citation>Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389-2430. doi: 10.1002/sim.2712</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2712</ArticleId><ArticleId IdType="pubmed">17031868</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhang MJ, Fine J. A proportional hazards regression model for the subdistribution with right-censored and left-truncated competing risks data. Stat Med. 2011;30(16):1933-1951. doi: 10.1002/sim.4264</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4264</ArticleId><ArticleId IdType="pmc">PMC3408877</ArticleId><ArticleId IdType="pubmed">21557288</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins C, Bennett I. A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time-to-event data. Res Synth Methods. 2018;9(3):352-360. doi: 10.1002/jrsm.1301</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1301</ArticleId><ArticleId IdType="pubmed">29707913</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, et al. <i>Cochrane Handbook for Systematic Reviews of Interventions</i> version 6.5 (updated August 2024). Accessed July 06, 2025. http://cochrane.org/authors/handbooks-and-manuals/handbook/current</Citation></Reference><Reference><Citation>Guyatt GH, Oxman AD, Vist GE, et al. ; GRADE Working Group . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. doi: 10.1136/bmj.39489.470347.AD</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39489.470347.AD</ArticleId><ArticleId IdType="pmc">PMC2335261</ArticleId><ArticleId IdType="pubmed">18436948</ArticleId></ArticleIdList></Reference><Reference><Citation>Makkar RR, Thourani VH, Mack MJ, et al. ; PARTNER 2 Investigators . Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med. 2020;382(9):799-809. doi: 10.1056/NEJMoa1910555</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1910555</ArticleId><ArticleId IdType="pubmed">31995682</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mieghem NM, Deeb GM, S&#xf8;ndergaard L, et al. ; SURTAVI Trial Investigators . Self-expanding transcatheter vs surgical aortic valve replacement in intermediate-risk patients: 5-year outcomes of the SURTAVI randomized clinical trial. JAMA Cardiol. 2022;7(10):1000-1008. doi: 10.1001/jamacardio.2022.2695</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2022.2695</ArticleId><ArticleId IdType="pmc">PMC9403849</ArticleId><ArticleId IdType="pubmed">36001335</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack MJ, Leon MB, Thourani VH, et al. ; PARTNER 3 Investigators . Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389(21):1949-1960. doi: 10.1056/NEJMoa2307447</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2307447</ArticleId><ArticleId IdType="pubmed">37874020</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest JK, Yakubov SJ, Deeb GM, et al. ; Low Risk Trial Investigators . 5-Year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis. J Am Coll Cardiol. 2025;85(15):1523-1532. doi: 10.1016/j.jacc.2025.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2025.03.004</ArticleId><ArticleId IdType="pubmed">40158212</ArticleId></ArticleIdList></Reference><Reference><Citation>Doenst T, Gregg AC, Kirov H, et al. Surgical versus transcatheter treatment of aortic valve stenosis-a meta-analysis of low-risk randomized trials with completed 5-year follow-up. Eur J Cardiothorac Surg. 2025;67(7):ezaf215. doi: 10.1093/ejcts/ezaf215</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezaf215</ArticleId><ArticleId IdType="pubmed">40580456</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf8;rgensen TH, Thyregod HGH, Ihlemann N, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J. 2021;42(30):2912-2919. doi: 10.1093/eurheartj/ehab375</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab375</ArticleId><ArticleId IdType="pmc">PMC8347457</ArticleId><ArticleId IdType="pubmed">34179981</ArticleId></ArticleIdList></Reference><Reference><Citation>Thyregod HGH, J&#xf8;rgensen TH, Ihlemann N, et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart J. 2024;45(13):1116-1124. doi: 10.1093/eurheartj/ehae043</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae043</ArticleId><ArticleId IdType="pmc">PMC10984572</ArticleId><ArticleId IdType="pubmed">38321820</ArticleId></ArticleIdList></Reference><Reference><Citation>Bisson A, Bodin A, Herbert J, et al. Pacemaker implantation after balloon- or self-expandable transcatheter aortic valve replacement in patients with aortic stenosis. J Am Heart Assoc. 2020;9(9):e015896. doi: 10.1161/JAHA.120.015896</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.015896</ArticleId><ArticleId IdType="pmc">PMC7428568</ArticleId><ArticleId IdType="pubmed">32362220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah W, Zahid S, Zaidi SR, et al. Predictors of permanent pacemaker implantation in patients undergoing transcatheter aortic valve replacement&#x2014;a systematic review and meta-analysis. J Am Heart Assoc. 2021;10(14):e020906. doi: 10.1161/JAHA.121.020906</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.020906</ArticleId><ArticleId IdType="pmc">PMC8483489</ArticleId><ArticleId IdType="pubmed">34259045</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>